Advancements in sequential and combination treatments for osteoporosis

doi:10.5246/jcps.2024.07.043

Abstract

Abstract:

Osteoporosis, a prevalent systemic degenerative disease, poses significant challenges to China’s national health, particularly due to complications such as fractures. Therapeutic interventions for osteoporosis primarily involve bone resorption inhibitors (antiresorptive) and bone formation promoters (anabolic). Numerous studies underscore the importance of sequential and combination treatments using diverse drug types. Such approaches have shown considerable efficacy in increasing bone mineral density, reducing fracture risk, and preventing the progression of osteoporosis. This article aimed to consolidate various sequential treatment schemes, offering valuable insights for clinicians in their practice.

Key words: Osteoporosis, Sequential treatment, Combination treatment

Supporting:

Jia Zheng, Ying Fu. Advancements in sequential and combination treatments for osteoporosis[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(7): 587-596.

Figures/Tables 1

References 41

[1]	Li, S.S.; He, S.H.; Xie, P.Y.; Li, W.; Zhang, X.X.; Li, T.F.; Li, D.F. Recent progresses in the treatment of osteoporosis. Front. Pharmacol. 2021, 12, 717065.
[2]	Adejuyigbe, B.; Kallini, J.; Chiou, D.; Kallini, J.R. Osteoporosis: molecular pathology, diagnostics, and therapeutics. Int. J. Mol. Sci. 2023, 24, 14583.
[3]	Wang, L.H.; Yu, W.; Yin, X.J.; Cui, L.J.; Tang, S.Y.; Jiang, N.; Cui, L.; Zhao, N.; Lin, Q.; Chen, L.; Lin, H.; Jin, X.L.; Dong, Z.; Ren, Z.P.; Hou, Z.L.; Zhang, Y.Q.; Zhong, J.M.; Cai, S.X.; Liu, Y.; Meng, R.L.; Deng, Y.; Ding, X.B.; Ma, J.G.; Xie, Z.J.; Shen, L.; Wu, W.; Zhang, M.M.; Ying, Q.F.; Zeng, Y.H.; Dong, J.; Cummings, S.R.; Li, Z.X.; Xia, W.B. Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study. JAMA Netw. Open. 2021, 4, e2121106.
[4]	Curtis, E.M.; Reginster, J.Y.; Al-Daghri, N.; Biver, E.; Brandi, M.L.; Cavalier, E.; Hadji, P.; Halbout, P.; Harvey, N.C.; Hiligsmann, M.; Javaid, M.K.; Kanis, J.A.; Kaufman, J.M.; Lamy, O.; Matijevic, R.; Perez, A.D.; Radermecker, R.P.; Rosa, M.M.; Thomas, T.; Thomasius, F.; Vlaskovska, M.; Rizzoli, R.; Cooper, C. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin. Exp. Res. 2022, 34, 695–714.
[5]	Zhang, Z.L. Guidelines for the diagnosis and treatment of primary osteoporosis. Chin. J. Osteoporos. Bone Mineral. Dis. 2022, 06, 573–611.
[6]	Li, M.; Zhang, Z.L.; Xia, W.B. The only way for drug treatment of osteoporosis: long-term sequential therapy. Chin. J. Osteoporos. Bone Mineral. Dis. 2021, 05, 441–446.
[7]	Adams, A.L.; Adams, J.L.; Raebel, M.A.; Tang, B.T.; Kuntz, J.L.; Vijayadeva, V.; McGlynn, E.A.; Gozansky, W.S. Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J. Bone Miner. Res. 2018, 33, 1252–1259.
[8]	Dito, G.; Lugaresi, M.; Degradi, C.; Guabello, G.; Longhi, M.; Corbetta, S. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study. Endocrine. 2023, 82, 181–189.
[9]	Bao, H.H.; Sun, G.W.; Wang, J.; Jia, P.; Hu, H. Observation of the efficacy of teriparatide and bisphosphonates in the sequential treatment of elderly patients with osteoporosis. J. Pract. Clin. Med. 2021, 16, 95–98.
[10]	Liu, T.C.; Hsu, C.N.; Lee, W.C.; Wang, S.W.; Huang, C.C.; Lee, Y.T.; Fu, C.M.; Chen, J.B.; Li, L.C. Denosumab is superior to raloxifene in lowering risks of mortality and ischemic stroke in osteoporotic women. Pharmaceuticals. 2023, 16, 222.
[11]	Eastell, R.; Nickelsen, T.; Marin, F.; Barker, C.; Hadji, P.; Farrerons, J.; Audran, M.; Boonen, S.; Brixen, K.; Gomes, J.M.; Obermayer-Pietsch, B.; Avramidis, A.; Sigurdsson, G.; Glüer, C.C. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of forsteo (EUROFORS). J. Bone Miner. Res. 2009, 24, 726–736.
[12]	Muschitz, C.; Kocijan, R.; Fahrleitner-Pammer, A.; Pavo, I.; Haschka, J.; Schima, W.; Kapiotis, S.; Resch, H. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density—the CONFORS study. J. Bone Miner. Res. 2014, 29, 1777–1785.
[13]	Bao, S.Y; Sun, J.; Zhang, Z.H. Meta-analysis of desumab after sequential therapy for postmenopausal osteoporosis. Eval. Anal. Drug Use Hosp. China. 2023, 07, 854–858.
[14]	Kendler, D.L.; Roux, C.; Benhamou, C.L.; Brown, J.P.; Lillestol, M.; Siddhanti, S.; Man, H.S.; San Martin, J.; Bone, H.G. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2010, 25, 72–81.
[15]	Recknor, C.; Czerwinski, E.; Bone, H.G.; Bonnick, S.L.; Binkley, N.; Palacios, S.; Moffett, A.; Siddhanti, S.; Ferreira, I.; Ghelani, P.; Wagman, R.B.; Hall, J.W.; Bolognese, M.A.; Benhamou, C.L. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet. Gynecol. 2013, 121, 1291–1299.
[16]	Anastasilakis, A.D.; Polyzos, S.A.; Gkiomisi, A.; Saridakis, Z.G.; Digkas, D.; Bisbinas, I.; Sakellariou, G.T.; Papatheodorou, A.; Kokkoris, P.; Makras, P. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos. Int. 2015, 26, 2521–2527.
[17]	Anastasilakis, A.D.; Papapoulos, S.E.; Polyzos, S.A.; Appelman-Dijkstra, N.M.; Makras, P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J. Bone Miner. Res. 2019, 34, 2220–2228.
[18]	Kondo, H.; Okimoto, N.; Yoshioka, T.; Akahoshi, S.; Fuse, Y.; Ogawa, T.; Okazaki, Y.; Katae, Y.; Tsukamoto, M.; Yamanaka, Y.; Kawasaki, M.; Sakai, A. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. J. Bone Miner. Metab. 2020, 38, 894–902.
[19]	Reid, I.R.; Horne, A.M.; Mihov, B.; Gamble, G.D. Bone loss after denosumab: only partial protection with zoledronate. Calcif. Tissue Int. 2017, 101, 371–374.
[20]	Sølling, A.S.; Harsløf, T.; Langdahl, B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J. Bone Miner. Res. 2021, 36, 1245–1254.
[21]	Finkelstein, J.S.; Wyland, J.J.; Lee, H.; Neer, R.M. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2010, 95, 1838–1845.
[22]	Sun, G.P.; Luo, X.X.; Pan, B. Prevention and drug combination sequential therapy for postmenopausal osteoporosis. Chin. Tissue Eng. Res. 2020, 33, 5385–5390.
[23]	Leder, B.Z.; Tsai, J.N.; Uihlein, A.V.; Wallace, P.M.; Lee, H.; Neer, R.M.; Burnett-Bowie, S.A M. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015, 386, 1147–1155.
[24]	Chandran, M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch. Endocrinol. Metab. 2022, 66, 724–738.
[25]	Tsai, J.N.; Lee, H.; David, N.L.; Eastell, R.; Leder, B.Z. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019, 7, 767–775.
[26]	Ngomdir, L.; Bharathwaj, V.V.; Nimmy, P.; Sindhu, R.; Dhamodhar, D.; Sathiyapriya, S.; Prabu, D.; RajMohan, M. Therapeutic use of anti-sclerostin antibody in the treatment of multiple myeloma: a systematic review. J. Pharm. Bioallied Sci. 2023, 15, S738–S741.
[27]	Wu, D.; Li, L.; Wen, Z.; Wang, G.B. Romosozumab in osteoporosis: yesterday, today and tomorrow. J. Transl. Med. 2023, 21, 668.
[28]	Lim, S.Y.; Bolster, M.B. Clinical utility of romosozumab in the management of osteoporosis: focus on patient selection and perspectives. Int. J. Womens Health. 2022, 14, 1733–1747.
[29]	McClung, M.R.; Grauer, A.; Boonen, S.; Bolognese, M.A.; Brown, J.P.; Diez-Perez, A.; Langdahl, B.L.; Reginster, J.Y.; Zanchetta, J.R.; Wasserman, S.M.; Katz, L.; Maddox, J.; Yang, Y.C.; Libanati, C.; Bone, H.G. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2014, 370, 412–420.
[30]	McClung, M.R.; Brown, J.P.; Diez-Perez, A.; Resch, H.; Caminis, J.; Meisner, P.; Bolognese, M.A.; Goemaere, S.; Bone, H.G.; Zanchetta, J.R.; Maddox, J.; Bray, S.; Grauer, A. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J. Bone Miner. Res. 2018, 33, 1397–1406.
[31]	Cosman, F.; Crittenden, D.B.; Adachi, J.D.; Binkley, N.; Czerwinski, E.; Ferrari, S.; Hofbauer, L.C.; Lau, E.; Lewiecki, E.M.; Miyauchi, A.; Zerbini, C.A.F.; Milmont, C.E.; Chen, L.; Maddox, J.; Meisner, P.D.; Libanati, C.; Grauer, A. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 2016, 375, 1532–1543.
[32]	Cosman, F.; Crittenden, D.B.; Ferrari, S.; Khan, A.; Lane, N.E.; Lippuner, K.; Matsumoto, T.; Milmont, C.E.; Libanati, C.; Grauer, A. FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J. Bone Miner. Res. 2018, 33, 1219–1226.
[33]	Calaf-Alsina, J.; Cano, A.; Guañabens, N.; Palacios, S.; Cancelo, M.J.; Castelo-Branco, C.; Larrainzar-Garijo, R.; Neyro, J.L.; Nogues, X.; Diez-Perez, A. Sequential management of postmenopausal health and osteoporosis: an update. Maturitas. 2023, 177, 107846.
[34]	Saag, K.G.; Petersen, J.; Brandi, M.L.; Karaplis, A.C.; Lorentzon, M.; Thomas, T.; Maddox, J.; Fan, M.; Meisner, P.D.; Grauer, A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 2017, 377, 1417–1427.
[35]	Wu, Z.R.; Huo, Y.N.; Gan, P.; Zhang, Y.J.; Wang, N.; Yang, R.J. Research status of sequential therapy of anti-osteoporosis drugs. Chin. J. Osteoporos. 2023, 01, 134–138.
[36]	McCloskey, E.V.; Johansson, H.; Harvey, N.C.; Lorentzon, M.; Shi, Y.; Kanis, J.A. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos. Int. 2021, 32, 1601–1608.
[37]	Curtis, E.M.; Reginster, J.Y.; Al-Daghri, N.; Biver, E.; Brandi, M.L.; Cavalier, E.; Hadji, P.; Halbout, P.; Harvey, N.C.; Hiligsmann, M.; Javaid, M.K.; Kanis, J.A.; Kaufman, J.M.; Lamy, O.; Matijevic, R.; Perez, A.D.; Radermecker, R.P.; Rosa, M.M.; Thomas, T.; Thomasius, F.; Vlaskovska, M.; Rizzoli, R.; Cooper, C. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin. Exp. Res. 2022, 34, 695–714.
[38]	Lee, D.Y.; Chung, Y.S. Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women. Sci. Rep. 2022, 12, 7142.
[39]	Ramchand, S.K.; David, N.L.; Leder, B.Z.; Tsai, J.N. Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT. J. Clin. Endocrinol. Metab. 2020, 105, 890–897.
[40]	Ramchand, S.K.; David, N.L.; Lee, H.; Bruce, M.; Bouxsein, M.L.; Leder, B.Z.; Tsai, J.N. Effects of combination denosumab and high-dose teriparatide administration on bone microarchitecture and estimated strength: the DATA-HD HR-pQCT study. J. Bone Miner. Res. 2021, 36, 41–51.
[41]	Wang, C.H.; Wei, G.; Qin, P.T.; Liu, D.F.; Chang, L.J.; Zhang, H.Y. Ren, Q. Sequential treatment of osteoporosis in middle-aged and elderly patients with tetramethanone soft capsule and zoledronic acid. Clin. Med. 2023, 01, 92–94.